Literature DB >> 29593027

T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Karolina I Woroniecka1,2, Kristen E Rhodin1, Pakawat Chongsathidkiet1,2, Kristin A Keith1, Peter E Fecci3,2.   

Abstract

A functional, replete T-cell repertoire is an integral component to adequate immune surveillance and to the initiation and maintenance of productive antitumor immune responses. Glioblastoma (GBM), however, is particularly adept at sabotaging antitumor immunity, eliciting severe T-cell dysfunction that is both qualitative and quantitative. Understanding and countering such dysfunction are among the keys to harnessing the otherwise stark potential of anticancer immune-based therapies. Although T-cell dysfunction in GBM has been long described, newer immunologic frameworks now exist for reclassifying T-cell deficits in a manner that better permits their study and reversal. Herein, we divide and discuss the various T-cell deficits elicited by GBM within the context of the five relevant categories: senescence, tolerance, anergy, exhaustion, and ignorance. Categorization is appropriately made according to the molecular bases of dysfunction. Likewise, we review the mechanisms by which GBM elicits each mode of T-cell dysfunction and discuss the emerging immunotherapeutic strategies designed to overcome them. Clin Cancer Res; 24(16); 3792-802. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 29593027      PMCID: PMC6095741          DOI: 10.1158/1078-0432.CCR-18-0047

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  111 in total

1.  Origin of concatemeric T7 DNA.

Authors:  J D Watson
Journal:  Nat New Biol       Date:  1972-10-18

Review 2.  The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.

Authors:  Amy B Heimberger; Ling-Yuan Kong; Mohamed Abou-Ghazal; Chantal Reina-Ortiz; David S Yang; Jun Wei; Wei Qiao; Robert J Schmittling; Gary E Archer; John H Sampson; Nobuyoshi Hiraoka; Waldemar Priebe; Gregory N Fuller; Raymond Sawaya
Journal:  Clin Neurosurg       Date:  2009

3.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Authors:  Karolina Woroniecka; Pakawat Chongsathidkiet; Kristen Rhodin; Hanna Kemeny; Cosette Dechant; S Harrison Farber; Aladine A Elsamadicy; Xiuyu Cui; Shohei Koyama; Christina Jackson; Landon J Hansen; Tanner M Johanns; Luis Sanchez-Perez; Vidyalakshmi Chandramohan; Yen-Rei Andrea Yu; Darell D Bigner; Amber Giles; Patrick Healy; Glenn Dranoff; Kent J Weinhold; Gavin P Dunn; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-02-07       Impact factor: 12.531

Review 4.  T-cell receptor excision circles in primary immunodeficiencies and other T-cell immune disorders.

Authors:  Raz Somech
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-12

5.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

6.  Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis.

Authors:  R B Effros; R Allsopp; C P Chiu; M A Hausner; K Hirji; L Wang; C B Harley; B Villeponteau; M D West; J V Giorgi
Journal:  AIDS       Date:  1996-07       Impact factor: 4.177

7.  Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery.

Authors:  Olesja Fornara; Jenny Odeberg; Nina Wolmer Solberg; Charlotte Tammik; Petra Skarman; Inti Peredo; Giuseppe Stragliotto; Afsar Rahbar; Cecilia Söderberg-Nauclér
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

8.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

9.  New insights on the role of CD8(+)CD57(+) T-cells in cancer.

Authors:  Richard C Wu; Patrick Hwu; Laszlo G Radvanyi
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

10.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Authors:  Prakash K Gupta; Jernej Godec; David Wolski; Emily Adland; Kathleen Yates; Kristen E Pauken; Cormac Cosgrove; Carola Ledderose; Wolfgang G Junger; Simon C Robson; E John Wherry; Galit Alter; Philip J R Goulder; Paul Klenerman; Arlene H Sharpe; Georg M Lauer; W Nicholas Haining
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

View more
  77 in total

Review 1.  Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Authors:  William Tomaszewski; Luis Sanchez-Perez; Thomas F Gajewski; John H Sampson
Journal:  Clin Cancer Res       Date:  2019-02-25       Impact factor: 12.531

Review 2.  Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.

Authors:  Meredith A Morgan; Christine E Canman
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

Review 3.  CAR T cells and checkpoint inhibition for the treatment of glioblastoma.

Authors:  Steven H Shen; Karolina Woroniecka; Andrew B Barbour; Peter E Fecci; Luis Sanchez-Perez; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2020-02-17       Impact factor: 4.388

4.  Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma.

Authors:  Karolina Woroniecka; Peter E Fecci
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 5.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

6.  Using viral vectors to deliver local immunotherapy to glioblastoma.

Authors:  Alexander F Haddad; Jacob S Young; Manish K Aghi
Journal:  Neurosurg Focus       Date:  2021-02       Impact factor: 4.047

7.  4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Cosette Dechant; Xiuyu Cui; Pakawat Chongsathidkiet; Daniel Wilkinson; Jessica Waibl-Polania; Luis Sanchez-Perez; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531

Review 8.  Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

Authors:  Bryan D Choi; Marcela V Maus; Carl H June; John H Sampson
Journal:  Clin Cancer Res       Date:  2018-11-16       Impact factor: 12.531

Review 9.  Immune Escape Mediated by Exosomal PD-L1 in Cancer.

Authors:  Sean E Lawler; Michal O Nowicki; Franz L Ricklefs; E Antonio Chiocca
Journal:  Adv Biosyst       Date:  2020-05-07

Review 10.  Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.

Authors:  Alexander F Haddad; Jacob S Young; Nikhil V Mummaneni; Noriyuki Kasahara; Manish K Aghi
Journal:  J Neurooncol       Date:  2021-01-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.